Gore implants first subject in ascending stent graph study
Gore initiated the early feasibility ARISE trial in 2018, publishing results in the Journal of Endovascular Therapy last year.
21 December 2023
21 December 2023
Gore initiated the early feasibility ARISE trial in 2018, publishing results in the Journal of Endovascular Therapy last year.
The company has said that its Remove study investigating the company’s Catuvab device has seen its last patient successfully finish the trial.
The assay utilises a qPCR reaction to measure the methylation levels of three DNA biomarkers specific to urothelial cancer.
The partnership pertains to two assays, notably the ocular T-POC TOTAL IgE and T-POC LACTOFERRIN imunoassays.
The Momentum systems are designed for stabilisation, fixation, and correction of the thoracolumbar and sacroiliac spine.
The company plans to enrol up to 30 patients in the study, with regular evaluations to further assess the treatment’s safety.
The US bioelectronic company has completed stage two enrolment of patients with Crohn’s disease or ulcerative colitis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.